Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
2Q Revenues: $5.2 billion (+16%)

2Q Earnings: $764.0 million (+8%)

YTD Revenues: $10.1 billion (+19%)

YTD Earnings: $1.4 billion  (+2%)

Comments: Pharmaceutical sales in the quarter were $4.5 billion (+16%). U.S. pharma sales were $2.6 billion (+17%) due to increased sales of Plavix, Abilify growth, and the HIV and hepatitis portfolio, as well as contributions from recent product launches, Orencia and Ixempra. Plavix sales were $1.4 billion (+17%) in the quarter. Abilify sales were up 28% to $529 million. Reyataz sales were $324 million (+28%). Sustiva Franchise revenues were $282 million (+21%). Baraclude sales were $136 million (+131%).  Orencia sales were $106 million (+93%). Ixempra sales were $26 million in the quarter. R&D expenses were up 9% to $826 million in the quarter. Acquired in-process R&D charges were $32 million, related to the acquisition of Kosan Biosciences, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters